Drug intelligence / Profile preview

Oligopin

Development stage
Unknown
Lead developer
DRT
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Oligopin is a highly purified standardized dry extract derived from the bark of the French maritime pine tree (Pinus pinaster). It is rich in oligomeric procyanidins (OPCs), bioflavonoids, catechins, and organic acids. The primary mechanism of action is its potent antioxidant activity—neutralizing free radicals and reducing oxidative stress. Oligopin also exhibits anti-inflammatory properties and has been shown to support cardiovascular health by increasing nitric oxide synthesis in blood vessel endothelium, promoting vasodilation and optimal circulation. Clinical studies indicate it is well-tolerated with a high safety margin; it has been evaluated for use in conditions such as cardiovascular disease and polycystic ovary syndrome (PCOS), though evidence for efficacy in PCOS is lacking[4][5][7]. Developed using advanced extraction techniques to ensure high purity and low tannin content compared to other pine bark extracts, Oligopin’s main applications are as a dietary supplement for antioxidant support, vascular health, skin health, urinary tract health, muscle function, post-menopausal wellness, vein health, and general reduction of oxidative stress[6][7][8].

Brand names
Oligopin
Other names
French maritime pine bark extractFMPBEPinus pinaster extract
02

Targets

NOS1 (nNOS)4R tau (Microtubule-associated protein tau (cis-pT231 conformation))

Beyond the preview

Go deeper on Oligopin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oligopin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call